EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 51 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,831 | -63.9% | 22,400 | -16.7% | 0.00% | – |
| Q2 2023 | $18,937 | -76.2% | 26,900 | -69.7% | 0.00% | – |
| Q1 2023 | $79,688 | -52.9% | 88,850 | -38.4% | 0.00% | – |
| Q4 2022 | $169,186 | -87.9% | 144,250 | -22.5% | 0.00% | -100.0% |
| Q3 2022 | $1,400,000 | +54.9% | 186,050 | +29.7% | 0.00% | +50.0% |
| Q2 2022 | $904,000 | -4.2% | 143,450 | +26.0% | 0.00% | 0.0% |
| Q1 2022 | $944,000 | +84.4% | 113,850 | +15.4% | 0.00% | +100.0% |
| Q4 2021 | $512,000 | -23.2% | 98,650 | -1.1% | 0.00% | 0.0% |
| Q3 2021 | $667,000 | -12.7% | 99,750 | +11.1% | 0.00% | -50.0% |
| Q2 2021 | $764,000 | +14.4% | 89,750 | +19.0% | 0.00% | 0.0% |
| Q1 2021 | $668,000 | -2.8% | 75,400 | +34.9% | 0.00% | 0.0% |
| Q4 2020 | $687,000 | +64.7% | 55,900 | +9.2% | 0.00% | +100.0% |
| Q3 2020 | $417,000 | +10325.0% | 51,200 | +12700.0% | 0.00% | – |
| Q2 2020 | $4,000 | – | 400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Telemetry Investments, L.L.C. | 135,848 | $2,024,000 | 6.74% |
| INTERWEST VENTURE MANAGEMENT CO | 764,918 | $11,397,000 | 4.91% |
| Knoll Capital Management, LLC | 350,238 | $5,219,000 | 3.85% |
| 683 Capital Management, LLC | 1,850,000 | $27,565,000 | 3.15% |
| Soleus Capital Management, L.P. | 205,407 | $3,060,000 | 2.95% |
| Broadfin Capital, LLC | 1,236,368 | $18,422,000 | 2.47% |
| P.A.W. CAPITAL CORP | 144,000 | $2,146,000 | 2.29% |
| MANGROVE PARTNERS IM, LLC | 847,284 | $12,625,000 | 1.85% |
| Corriente Advisors, LLC | 203,898 | $3,038,000 | 1.63% |
| Trellus Management Company, LLC | 63,850 | $951,000 | 1.59% |